Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Primary Carnitine Deficiency and Cardiomyopathy

  • Fu, Lijun (Department of Cardiology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine) ;
  • Huang, Meirong (Department of Cardiology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine) ;
  • Chen, Shubao (Department of Cardiology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine)
  • Published : 2013.12.30
⟨ Previous Next ⟩

Abstract

Carnitine is essential for the transfer of long-chain fatty acids from the cytosol into mitochondria for subsequent ${\beta}$-oxidation. A lack of carnitine results in impaired energy production from long-chain fatty acids, especially during periods of fasting or stress. Primary carnitine deficiency (PCD) is an autosomal recessive disorder of mitochondrial ${\beta}$-oxidation resulting from defective carnitine transport and is one of the rare treatable etiologies of metabolic cardiomyopathies. Patients affected with the disease may present with acute metabolic decompensation during infancy or with severe cardiomyopathy in childhood. Early recognition of the disease and treatment with L-carnitine may be life-saving. In this review article, the pathophysiology, clinical presentation, diagnosis, treatment and prognosis of PCD are discussed, with a focus on cardiac involvements.

Keywords

References

  1. Cox GF, Sleeper LA, Lowe AM, et al. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics 2006;118:1519-31. https://doi.org/10.1542/peds.2006-0163
  2. Cox GF. Diagnostic Approaches to Pediatric Cardiomyopathy of Metabolic Genetic Etiologies and Their Relation to Therapy. Prog Pediatr Cardiol 2007;24:15-25. https://doi.org/10.1016/j.ppedcard.2007.08.013
  3. Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 1981;305:385-90. https://doi.org/10.1056/NEJM198108133050707
  4. Waber LJ, Valle D, Neill C, DiMauro S, Shug A. Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 1982;101:700-5. https://doi.org/10.1016/S0022-3476(82)80294-1
  5. Pierpont ME, Breningstall GN, Stanley CA, Singh A. Familial carnitine transporter defect: a treatable cause of cardiomyopathy in children. Am Heart J 2000;139(2 Pt 3):S96-106. https://doi.org/10.1067/mhj.2000.103921
  6. Rebouche CJ. Carnitine function and requirements during the life cycle. FASEB J 1992;6:3379-86.
  7. Glube N, Closs E, Langguth P. OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol Pharm 2007;4:160-8. https://doi.org/10.1021/mp060073a
  8. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010;7:30. https://doi.org/10.1186/1743-7075-7-30
  9. Koizumi A, Nozaki J, Ohura T, et al. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 1999;8:2247-54. https://doi.org/10.1093/hmg/8.12.2247
  10. Lund AM, Joensen F, Hougaard DM, et al. Carnitine transporter and holocarboxylase synthetase deficiencies in The Faroe Islands. J Inherit Metab Dis 2007;30:341-9. https://doi.org/10.1007/s10545-007-0527-9
  11. Rasmussen J, Nielsen OW, Janzen N, et al. Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands. J Inherit Metab Dis 2013. [Epub ahead of print]
  12. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999;21:91-4. https://doi.org/10.1038/5030
  13. Wang Y, Ye J, Ganapathy V, Longo N. Mutations in the organic cation/ carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A 1999;96:2356-60. https://doi.org/10.1073/pnas.96.5.2356
  14. Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998;273:20378-82. https://doi.org/10.1074/jbc.273.32.20378
  15. Wu X, Prasad PD, Leibach FH, Ganapathy V. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 1998;246:589-95. https://doi.org/10.1006/bbrc.1998.8669
  16. Scaglia F, Wang Y, Singh RH, et al. Defective urinary carnitine transport in heterozygotes for primary carnitine deficiency. Genet Med 1998;1: 34-9. https://doi.org/10.1097/00125817-199811000-00008
  17. Stanley CA, Bennett MJ. Defects in Metabolism of Lipid. In: Kliegman RM, Behrman RE, Stanton BF, St. Geme J, Schor N, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: W.B. Saunders Company;2011. p.460-1.
  18. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998;180:33-41. https://doi.org/10.1023/A:1006826620218
  19. Chapoy PR, Angelini C, Brown WJ, Stiff JE, Shug AL, Cederbaum SD. Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med 1980;303:1389-94. https://doi.org/10.1056/NEJM198012113032403
  20. Shibbani K, Fahed A, Al-Shaar L, et al. Primary carnitine deficiency: novel mutations and insights into the cardiac phenotype. Clin Genet 2013. [Epub ahead of print]
  21. Kilic M, Ozgul RK, Coskun T, et al. Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency. JIMD Rep 2012;3:17-23.
  22. Fu LJ, Chen SB, Han LS, et al. [Clinical presentation and therapeutic outcomes of carnitine deficiency-induced cardiomyopathy]. Zhonghua Er Ke Za Zhi 2012;50:929-34.
  23. Stanley CA, DeLeeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991;30:709-16. https://doi.org/10.1002/ana.410300512
  24. Rasmussen J, Kober L, Lund AM, Nielsen OW. Primary Carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screening. J Inherit Metab Dis 2013. [Epub ahead of print]
  25. Lee NC, Tang NL, Chien YH, et al. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol Genet Metab 2010;100:46-50. https://doi.org/10.1016/j.ymgme.2009.12.015
  26. De Biase I, Champaigne NL, Schroer R, Pollard LM, Longo N, Wood T. Primary Carnitine Deficiency Presents Atypically with Long QT Syndrome: A Case Report. JIMD Rep 2012;2:87-90.
  27. Amat di San Filippo C, Taylor MR, Mestroni L, Botto LD, Longo N. Cardiomyopathy and carnitine deficiency. Mol Genet Metab 2008;94: 162-6. https://doi.org/10.1016/j.ymgme.2008.02.002
  28. Labarthe F, Benoist JF, Peralta M, et al. Primary carnitine uptake deficiency is associated with short QT syndrome and ventricular fibrillation. 11th International Congress of Inborn errors of Metabolism, San Diego CA, Mol Genet Metab 2009;98:55-6 (Poster 327).
  29. Rijlaarsdam RS, van Spronsen FJ, Bink-Boelkens MT, et al. Ventricular fibrillation without overt cardiomyopathy as first presentation of organic cation transporter 2-deficiency in adolescence. Pacing Clin Electrophysiol 2004;27:675-6. https://doi.org/10.1111/j.1540-8159.2004.00507.x
  30. El-Hattab AW, Li FY, Shen J, et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med 2010;12:19-24. https://doi.org/10.1097/GIM.0b013e3181c5e6f7
  31. Rinaldo P, Stanley CA, Hsu BY, Sanchez LA, Stern HJ. Sudden neonatal death in carnitine transporter deficiency. J Pediatr 1997;131:304-5. https://doi.org/10.1016/S0022-3476(97)70171-9
  32. Rasmussen J, Nielsen OW, Lund AM, Køber L, Djurhuus H. Primary carnitine deficiency and pivalic acid exposure causing encephalopathy and fatal cardiac events. J Inherit Metab Dis 2013;36:35-41. https://doi.org/10.1007/s10545-012-9488-8
  33. Matsuishi T, Hirata K, Terasawa K, et al. Successful carnitine treatment in two siblings having lipid storage myopathy with hypertrophic cardiomyopathy. Neuropediatrics 1985;16:6-12. https://doi.org/10.1055/s-2008-1052536
  34. Tein I, De Vivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res 1990;28:247-55. https://doi.org/10.1203/00006450-199009000-00020
  35. Ferro F, Ouillé A, Tran TA, et al. Long-chain acylcarnitines regulate the hERG channel. PLoS One 2012;7:e41686. https://doi.org/10.1371/journal.pone.0041686
  36. Garavaglia B, Uziel G, Dworzak F, Carrara F, DiDonato S. Primary carnitine deficiency: heterozygote and intrafamilial phenotypic variation. Neurology 1991;41:1691-3. https://doi.org/10.1212/WNL.41.10.1691
  37. Xiaofei E, Wada Y, Dakeishi M, et al. Age-associated cardiomyopathy in heterozygous carrier mice of a pathological mutation of carnitine transporter gene, OCTN2. J Gerontol A Biol Sci Med Sci 2002;57:B270-8. https://doi.org/10.1093/gerona/57.7.B270
  38. Takahashi R, Asai T, Murakami H, et al. Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. Hypertension 2007;50:497-502. https://doi.org/10.1161/HYPERTENSIONAHA.107.088609
  39. Sarafoglou K, Tridgell AH, Bentler K, Redlinger-Grosse K, Berry SA, Schimmenti LA. Cardiac conduction improvement in two heterozygotes for primary carnitine deficiency on L-carnitine supplementation. Clin Genet 2010;78:191-4. https://doi.org/10.1111/j.1399-0004.2009.01368.x
  40. Wang Y, Taroni F, Garavaglia B, Longo N. Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype correlation. Hum Mutat 2000;16:401-7. https://doi.org/10.1002/1098-1004(200011)16:5<401::AID-HUMU4>3.0.CO;2-J
  41. Spiekerkoetter U, Huener G, Baykal T, et al. Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. J Inherit Metab Dis 2003;26:613-5. https://doi.org/10.1023/A:1025968502527
  42. Rose EC, di San Filippo CA, Ndukwe Erlingsson UC, Ardon O, Pasquali M, Longo N. Genotype-phenotype correlation in primary carnitine deficiency. Hum Mutat 2012;33:118-23. https://doi.org/10.1002/humu.21607
  43. Yamak A, Bitar F, Karam P, Nemer G. Exclusive cardiac dysfunction in familial primary carnitine deficiency cases: a genotype-phenotype correlation. Clin Genet 2007;72:59-62. https://doi.org/10.1111/j.1399-0004.2007.00814.x
  44. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2012;7:68. https://doi.org/10.1186/1750-1172-7-68
  45. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142C:77-85. https://doi.org/10.1002/ajmg.c.30087
  46. Helton E, Darragh R, Francis P, et al. Metabolic aspects of myocardial disease and a role for L-carnitine in the treatment of childhood cardiomyopathy. Pediatrics 2000;105:1260-70.
  47. Kothari SS, Sharma M. L-carnitine in children with idiopathic dilated cardiomyopathy. Indian Heart J 1998;50:59-61.
  48. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000; 139(2 Pt 3):S120-3. https://doi.org/10.1067/mhj.2000.103917
  49. Agnetti A, Bitton L, Tchana B, Raymond A, Carano N. Primary carnitine deficiency dilated cardiomyopathy: 28 years follow-up. Int J Cardiol 2013;162:e34-5. https://doi.org/10.1016/j.ijcard.2012.05.038
  50. Cederbaum SD, Koo-McCoy S, Tein I, et al. Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol Genet Metab 2002;77:195-201. https://doi.org/10.1016/S1096-7192(02)00169-5
  51. Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004;1033:42-51. https://doi.org/10.1196/annals.1320.004

Cited by

  1. Validation of a Stability-Indicating RP-HPLC Method for Determination of L -Carnitine in Tablets vol.2014, pp.None, 2013, https://doi.org/10.1155/2014/481059
  2. Identification of SLC22A5 Gene Mutation in a Family with Carnitine Uptake Defect vol.2015, pp.None, 2015, https://doi.org/10.1155/2015/259627
  3. Cardiac manifestations in children with inborn errors of metabolism vol.54, pp.8, 2017, https://doi.org/10.1007/s13312-017-1131-1
  4. Exome sequencing identifies primary carnitine deficiency in a family with cardiomyopathy and sudden death vol.25, pp.6, 2013, https://doi.org/10.1038/ejhg.2017.22
  5. Primary Carnitine Deficiency: A Rare, Reversible Metabolic Cardiomyopathy vol.2018, pp.None, 2013, https://doi.org/10.1155/2018/3232105
  6. Scientific Papers and Patents on Substances with Unproven Effects vol.13, pp.1, 2019, https://doi.org/10.2174/1872211313666190307162041
  7. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era vol.178, pp.3, 2013, https://doi.org/10.1007/s00431-018-03315-2
  8. ITPase deficiency causes a Martsolf-like syndrome with a lethal infantile dilated cardiomyopathy vol.15, pp.3, 2013, https://doi.org/10.1371/journal.pgen.1007605
  9. Respiratory manifestations in inherited metabolic diseases: 6‐year single‐center experience vol.54, pp.8, 2013, https://doi.org/10.1002/ppul.24359
  10. Learning from studying very rare cardiac conditions: the example of short QT syndrome vol.3, pp.1, 2013, https://doi.org/10.1186/s40949-019-0024-7
  11. General anesthesia with cisatracurium and sevoflurane for a patient with primary carnitine deficiency receiving L-carnitine therapy : A case report vol.100, pp.38, 2013, https://doi.org/10.1097/md.0000000000027333
  12. Carnitine deficiency among hospitalized pediatric patients: A retrospective study of critically ill patients receiving extracorporeal membrane oxygenation therapy vol.45, pp.8, 2013, https://doi.org/10.1002/jpen.2255